KRAS overexpression
|
Melanoma
|
KRAS overexpression
|
Melanoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
KRAS overexpression
|
Uveal Melanoma
|
KRAS overexpression
|
Uveal Melanoma
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|